Last updated on March 2019

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases


Brief description of study

This randomized phase II trial studies how well cisplatin works with or without veliparib in treating patients with triple-negative breast cancer and/or BRCA mutation-associated breast cancer that has come back or has or has not spread to the brain. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known if cisplatin is more effective with or without veliparib in treating patients with triple-negative and/or BRCA mutation-associated breast cancer.

Detailed Study Description

PRIMARY OBJECTIVES:

I. To compare the efficacy of cisplatin with or without ABT-888 (veliparib) on progression-free survival (PFS) in each of the following groups: patients with germline BRCA (gBRCA) mutation-associated breast cancer, patients with germline BRCA wild-type breast cancer who have evidence of BRCAness phenotype, and patients with germline BRCA wild-type breast cancer who do not have evidence of BRCAness phenotype.

II. To compare the efficacy of cisplatin with or without ABT-888 on PFS in patients with triple negative and/or gBRCA mutation-associated breast cancer and brain metastases. (Brain Metastases Cohort)

SECONDARY OBJECTIVES:

I. For patients with gBRCA mutation associated breast cancer or triple-negative breast cancer (TNBC) with or without BRCAness phenotype, to compare the efficacy of cisplatin with or without ABT-888 on overall survival (OS), response rate, and clinical benefit rate.

II. To compare the differential benefit of ABT-888 across the three groups using both PFS and OS as outcomes.

III. For patients in the brain metastases cohort, to compare the efficacy of cisplatin with or without ABT-888 on OS.

IV. For patients in the brain metastases cohort, to compare the efficacy of cisplatin with or without ABT-888 on intracranial and extracranial response rates (intracranial by Response Assessment Neuro-Oncology Criteria [RANO] and extracranial by Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1]).

V. To compare toxicities of ABT-888 to placebo in each of the four groups separately.

TRANSLATIONAL OBJECTIVES:

I. To evaluate the impact of homologous recombination deficiency score (independent of other BRCAness markers) on response rate (RR) and PFS in patients treated with chemotherapy versus chemotherapy plus ABT-888.

II. To evaluate the overlap among various markers utilized to define the BRCAness phenotype.

III. To evaluate the combined impact of PAM50 basal subtype and BRCAness phenotype on RR and PFS in patients treated with chemotherapy versus chemotherapy plus ABT-888.

IV. To evaluate the impact of BRCA1 mRNA expression (independent other BRCAness markers) on response rate (RR) and PFS in patients treated with chemotherapy versus chemotherapy plus ABT-888.

V. Application of somatic BRCAness phenotype markers on metastatic tumor tissue to identify patients likely to benefit from platinum-based therapy and ABT-888.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive cisplatin intravenously (IV) over 1 hour on day 1 and placebo orally (PO) twice daily (BID) on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive cisplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 9 weeks for 54 weeks, every 18 weeks until progression, and then every 6 months for up to 5 years after progression.

Clinical Study Identifier: NCT02595905

Contact Investigators or Research Sites near you

Start Over

Dana Zakalik

Michigan Cancer Specialists
Roseville, MI United States
  Connect »

Christopher M. Reynolds

Advanced Breast Care Center PLLC
Warren, MI United States
2.44miles
  Connect »

Christopher M. Reynolds

Bhadresh Nayak MD PC-Warren
Warren, MI United States
3.06miles
  Connect »

Christopher M. Reynolds

Great Lakes Cancer Management Specialists-Macomb Professional Building
Warren, MI United States
3.06miles
  Connect »

Christopher M. Reynolds

Macomb Hematology Oncology PC
Warren, MI United States
3.06miles
  Connect »

Christopher M. Reynolds

Michigan Breast Specialists-Warren
Warren, MI United States
3.06miles
  Connect »

Christopher M. Reynolds

Saint John Macomb-Oakland Hospital
Warren, MI United States
3.06miles
  Connect »

Christopher M. Reynolds

Bhadresh Nayak MD PC-Sterling Heights
Sterling Heights, MI United States
5.05miles
  Connect »

Dana Zakalik

Premier Hematology Oncology Care
Sterling Heights, MI United States
5.05miles
  Connect »

Christopher M. Reynolds

Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
Grosse Pointe Woods, MI United States
5.61miles
  Connect »

Christopher M. Reynolds

Lymphoma Clinic of Michigan
Grosse Pointe Woods, MI United States
5.61miles
  Connect »

Christopher M. Reynolds

Michigan Breast Specialists-Grosse Pointe Woods
Grosse Pointe Woods, MI United States
5.61miles
  Connect »

Christopher M. Reynolds

Ascension Saint John Hospital
Detroit, MI United States
5.61miles
  Connect »

Ding Wang

Henry Ford Macomb Hospital-Clinton Township
Clinton Township, MI United States
8.18miles
  Connect »

Dana Zakalik

William Beaumont Hospital-Grosse Point
Grosse Pointe, MI United States
8.23miles
  Connect »

Dana Zakalik

Mitchell Folbe MD PC
Sterling Heights, MI United States
8.97miles
  Connect »

Christopher M. Reynolds

Great Lakes Cancer Management Specialists-Macomb Medical Campus
Macomb, MI United States
9.94miles
  Connect »

Christopher M. Reynolds

Michigan Breast Specialists-Macomb Township
Macomb, MI United States
9.94miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.